Catalyst Event
Everest Medicines Limited (1952) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
6/2/2026, 12:00:00 AM
Announced an exclusive licensing agreement to out-license civorebrutinib to Travere Therapeutics for $112.5M upfront and up to $1.03B in milestones on 2026-06-02; high impact estimated due to the substantial deal value.
Korean Translation
2026년 6월 2일 시보레브루티닙 기술수출 계약 체결을 발표함. 대규모 계약 규모에 따라 10% 이상의 높은 시장 영향력이 예상됨.
Related Recent Events
Pacific Biosciences of California Inc (PACB) · Earnings Release
Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Ex-dividend date on 2026-06-29 for the 2025 final dividend of HK$0.0418 per share; Low importance justified by it being a standard technical adjustment scheduled
6/29/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Annual General Meeting on 2026-06-25 to vote on 2025 financial statements and a HK$0.0418 dividend; Low importance justified by the routine nature of the meeting scheduled
6/25/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
An extraordinary general meeting is scheduled on 2026-06-25 to vote on a new executive remuneration system and a 10% H-share repurchase mandate; 1% price impact expected.
6/25/2026, 12:00:00 AM